Slides on Pediatric Psoriasis: Informed Decisions That Improve Clinical Outcomes

CCO slides on when to use interleukins inhibitors in psoriatis arthritis: biologic dmard or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab.

Vinod Chandran, MBBS, MD, DM, PhD Alexis Ogdie, MD, MSCE Released: December 29, 2020

CME for CCO on when to use interleukin inhibitors in psoriatis arthritis: biologic DMARD or MTX naive? IL-17A secukinumab, ixekizumab; IL-12/23 ustekinumab

Vinod Chandran, MBBS, MD, DM, PhD Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Released: December 29, 2020 Expired: December 28, 2021

Guidelines and Therapies

Head-to-Head Studies

Hear from expert Jim Treat, MD, on optimizing care of pediatric patients with plaque psoriasis, including systemic options, working with families, and more

Jim Treat, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 21, 2020 Expired: December 20, 2021

New from EULAR 2020, Clinical Care Options (CCO): adults with immune-mediated inflammatory disease report biologic-associated fatigue in Dutch Biologic Monitor